This observational, multicentric prospective study aims to understand the prevalence and burden of antimicrobial resistance (AMR) in people with chronic lung diseases (CLD) across the globe, understanding also geographical variability and the risk factors for acquiring AMR.
The primary objective is to understand the prevalence and burden of AMR in CLD both at a local and gloval level.
Secondary objectives include: 1) understanding susceptibilities models of high priority pathogens in people with CLD; 2) understanding geographic variability in the prevalence of AMR in CLD; 3) analysing risk factors for AMR in CLD Participants will be recruited
Patients of all ages with any chronic lung disease who, for clinical practice, underwent testingof at least one respiratory biological sample (sputum culture; bronchoaspirate; bronchoalveolar lavage; nasal swab; throat swab) within the 12 months prior to the visit.
Patients attending an outpatient clinic or hospitalized during the study period
Patients who have not signed the informed consent form
Absence of data in the patient record
The study will include patients of all ages with all kinds of chronic lung disease who underwent testing of at least one respiratory sample in the previous 12 months who attend a respiratory outpatient clinic or are hospitalized during the yearly two two-weeks recruitment windows.
Cohort
Prospective
Not listed
Prevalence of antimicrobial resistance in chronic lung diseases
Prevalence and burden of antimicrobial resistance in chronic lung diseases at both local and global levels.
The antimicrobial susceptibility profile of high-priority resistant pathogens
The antimicrobial susceptibility profile of high-priority resistant pathogens in chronic lung diseases.
The geographical variation in the prevalence of antimicrobial resistance
The geographical variation in the prevalence of antimicrobial resistance and antimicrobial susceptibility profiles
The risk factors for antimicrobial resistance in chronic lung diseases.
The risk factors for antimicrobial resistance in chronic lung diseases.
Click on the lead sponsor to view all of their trials.
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Lead sponsor
European Respiratory Society
Collaborator
Royal Brompton & Harefield NHS Foundation Trust
Collaborator
Imperial College London
Collaborator
